Mechanisms of antiparkinsonian anticholinergic therapy revisited

RM Paz, MG Murer - Neuroscience, 2021 - Elsevier
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …
被引用次数：12 相关文章

Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited

RM Paz, MG Murer - Neuroscience, 2021 - Elsevier
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …

Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited

RM Paz, MG Murer - 2021 - ri.conicet.gov.ar
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …

Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited

RM Paz, MG Murer - Neuroscience, 2021 - ibroneuroscience.org
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …

Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.

RM Paz, MG Murer - Neuroscience, 2021 - europepmc.org
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …

Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited

RM Paz, MG Murer - Neuroscience, 2021 - pubmed.ncbi.nlm.nih.gov
Before the advent of L-DOPA, the gold standard symptomatic therapy for Parkinson's
disease (PD), anticholinergic drugs (muscarinic receptor antagonists) were the preferred …